Mylan Launches Hulio (adalimumab- biosimilar) in EU for Autoimmune Diseases

Share this

Mylan Launches Hulio (adalimumab- biosimilar) in EU for Autoimmune Diseases


  • AbbVie's Humira biosimilar- Hulio received EU approval in Sep 2018- reviewing CHMP approval which included biosimilarity data regarding analytical- functional- clinical and immunogenicity of Hulio with Humira
  • The launch of Hulio post EU approval is available in all 28 EU member countries including Norway- Iceland and Liechtenstein. In July- 2018 Humira had brand sales of ~$4.3B in EU
  • Adalimumab IV is a TNFi indicated for treatment of autoimmune diseases. In H1’18- Mylan and Kyowa Kirin entered into a collaboration for Hulio’s commercialization in EU

Ref: Mylan| Image: Investor Business Daily  


Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions